The trading price of Abbvie Inc (NYSE:ABBV) floating lower at last check on current market day and closing at $169.45, -1.83% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it has been fluctuating between $168.06 and $170.45. The company’s P/E ratio in the trailing 12-month period was 59.10, while its 5Y monthly beta was 0.613. In examining the 52-week price action we see that the stock hit a 52-week high of $207.32 and a 52-week low of $153.58. Over the past month, the stock has lost -2.06% in value.
Abbvie Inc, whose market valuation is $299.44 billion at the time of this writing, is expected to release its quarterly earnings report in February. The dividend yield on the company stock is 3.71%, while its Forward Dividend ratio is 6.29. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by 2.98 per share this quarter, however they have predicted annual earnings per share of 10.94 for current year and 12.2 for next year.
Analysts have forecast the company to bring in revenue of 14.82B for the current quarter, with the likely lows of 14.6B and highs of 15.02B. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 56.05B.
On the technical side, indicators suggest ABBV has a 50% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 50% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned ABBV a recommendation rating is 27. Out of them, 7 rate it a Hold, while 20 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Abbvie Inc (ABBV) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 7.24, which symbolizes a positive outlook. A quick review shows that ABBV’s price is currently -3.99% off the SMA20 and -3.84% off the SMA50. The RSI metric on the 14-day chart is currently showing 37.60, and weekly volatility stands at 2.23%. When measured over the past 30 days, the indicator reaches 1.88%. Abbvie Inc (NYSE:ABBV)’s beta value is currently sitting at 0.56, while the Average True Range indicator is currently displaying 3.69. With analysts defining $203-$226 as the low and high price targets, we arrive at a consensus price target of $209 for the trailing 12-month period. The current price is about -19.8% off the estimated low and -33.37% off the forecast high, based on this estimate. Investors will be thrilled if ABBV’s share price rises to $209, which is the median consensus price. At that level, ABBV’s share price would be -23.34% below current price.
To see how Abbvie Inc stock has been performing today in comparison to its peers in the industry, here are the numbers: ABBV stock’s performance was -1.83% at last check in today’s session, and 2.84% in the past year. Abbvie Inc has a P/E ratio of 59.10.
An evaluation of the daily trading volume of Abbvie Inc (NYSE:ABBV) indicates that the 3-month average is 6.48 million. However, this figure has increased over the past 10 days to an average of 6.03.
Currently, records show that 1.77 billion of the company’s shares remain outstanding. The insiders hold 0.08% of outstanding shares, whereas institutions hold 72.96%. The stats also highlight that short interest as of 2024-12-31, stood at 17.0 million shares, resulting in a short ratio of 2.95 at that time. From this, we can conclude that short interest is 96.00 of the company’s total outstanding shares. It is noteworthy that short shares in December were down slightly from the previous month’s figure, which was 19.32 million. However, since the stock’s price has seen -4.64% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
